Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock

BMC Immunology

Volumn 14, Issue 1, 2013, Pages

  Bojalil, Rafael ^a,b   Mata González, María Teresa ^c   Sánchez Muñoz, Fausto ^a   Yee, Yepci ^a   Argueta, Iván ^a   Bolaños, Lucía ^a   Amezcua Guerra, Luis Manuel ^a   Camacho Villegas, Tanya Amanda ^d,e   Sánchez Castrejón, Edna ^e   García Ubbelohde, Walter Jakob ^c   Licea Navarro, Alexei Fedorovish ^e   Márquez Velasco, Ricardo ^a,f   Paniagua Solís, Jorge Fernando ^c,g  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^c Laboratorios Silanes   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^e CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA   (Mexico)

^f UNIVERSIDAD DEL VALLE DE MÉXICO   (Mexico)

^g

^h Spain

Author keywords

Anti TNF; Endotoxic shock; Inflammation; Sepsis; VNAR

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRITE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY NAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; INFLAMMATION; LETHALITY; MALE; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEPTIC SHOCK;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED BALB C; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; SHOCK, SEPTIC; SINGLE-DOMAIN ANTIBODIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875525048     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-14-17     Document Type: Article

References (41)

1. López-Bojórquez LN, Zentella-Dehesa A, Reyes-Terán G. Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res 2004, 35:465-479. 10.1016/j.arcmed.2004.07.006, 15631870.
2. Tetta C, Fonsato V, Ronco C, Camussi G. Recent insights into pathogenesis of severe sepsis. Crit Care Resusc 2005, 7:32-39.
3. Macdonald J, Galley HF, Webster NR. Oxidative stress gene expression in sepsis. Br J Anaesth 2003, 90:221-232. 10.1093/bja/aeg034, 12538380.
4. Fujii E, Yoshioka T, Ishida H, Irie K, Muraki T. Evaluation of iNOS- dependent and independent mechanisms of the microvascular permeability change induced by lipopolysaccharide. Br J Pharmacol 2000, 130:90-94. 10.1038/sj.bjp.0703277, 1572034, 10781002.
5. Zeerleder S, Hack E, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005, 128:2864-2875. 10.1378/chest.128.4.2864, 16236964.
6. Remick D, Manohar P, Bolgos G, Rodríguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995, 4:89-95. 10.1097/00024382-199508000-00002, 7496903.
7. Márquez-Velasco R, Bojalil R, Buelna A, Flores-Guzmán F, Estevez-Ramirez J, Laguna J. Anti-tumor necrosis factor alpha F(ab')2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. Inflamm Res 2006, 5:378-384.
8. Karima R, Matsumoto S, Higashi H, Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999, 5:123-132. 10.1016/S1357-4310(98)01430-0, 10203736.
9. Juarez K, Dubberke G, Lugo P, Koch-Nolte F, Buck F, Haag F, Licea A. Monoclonal antibodies for the identification and purification of vNAR domains and IgNAR immunoglobulins from the horn shark Heterodontus francisci. Hybridoma (Larchmt) 2011, 30:323-329.
10. Nuttall S, Humberstone K, Krishnan U, Carmichael J, Doughty L, Hattarki M. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004, 55:187-197. 10.1002/prot.20005, 14997552.
11. Henderson KA, Strelstov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH. Structure of an VNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malaria strain recognition. Structure 2007, 15:1452-1466. 10.1016/j.str.2007.09.011, 17997971.
12. Liu JL, Anderson GP, Delehanty JB, Baumann R, Hayhurst A, Goldman ER. Selection of cholera toxin specific VNAR single- domain antibodies from a naïve shark library. Selection of cholera toxin specific VNAR single-domain antibodies from a naive shark library. Mol Immunol 2007, 44:1775-83. 10.1016/j.molimm.2006.07.299, 17007931.
13. Mengozzi M, Ghezzi P. Cytokine down-regulation in endotoxin tolerance. Eur Cytokine Netw 1993, 4:89-98.
14. Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, Dolezal O. Targeting the hepatitis B virus precore antigen with a novel VNAR single variable domain intrabody. Virology 2011, 41:132-141.
15. Evans T, Carpenter A, Silva A, Cohen J. Differentitial effects of monoclonal antibodies to tumor necrosis factor and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis. Infect Immun 1992, 60:4133-4139. 257445, 1383147.
16. Karzai W, Cui X, Mehlton B, Straube E, Hartung T, Gerstenberger E. Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiology 2003, 99:81-89. 10.1097/00000542-200307000-00016, 12826846.
17. Wang W, Wang EQ, Balthasar JP. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics. Clin Pharmacol Ther 2008, 84:548-558. 10.1038/clpt.2008.170, 18784655.
18. Holliger P, Hudson P. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136. 10.1038/nbt1142, 16151406.
19. Cortez-Retamozo V, Lauwereys M, Hassanzadeh G, Gobert M, Conrath K, Muyldermans S. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002, 98:456-462. 10.1002/ijc.10212, 11920600.
20. Dhainaut JF, Marin N, Mignon A, Vinsonneau A. Hepatic response to sepsis: Interactions between coagulation and inflammatory processes. Crit Care Med 2001, 29:S42-S47.
21. Wu RQ, Xu YX, Song XH, Chen LJ, Meng XJ. Adhesion molecule and proinflammatory cytokine gene expression in hepatic sinusoidal endothelial cells following cecal ligation and puncture. World J Gastroenterol 2001, 7:128-130.
22. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009, 198:157-174. 10.1007/s00430-009-0116-7, 2714450, 19529959.
23. Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993, 177:547-550. 10.1084/jem.177.2.547, 2190913, 8426124.
24. Kato T, Murata A, Ishida H, Toda H, Tanaka N, Hayashida H. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 1995, 39:1336-1340. 10.1128/AAC.39.6.1336, 162737, 7574526.
25. Latifi SQ, O'Riordan MA, Levine AD. Interleukin 10 controls the onset of irreversible septic shock. Infect Immun 2002, 70:4441-4446. 10.1128/IAI.70.8.4441-4446.2002, 128185, 12117955.
26. Lu J, Sadri N, Schneider RJ. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev 2006, 20:3174-3184. 10.1101/gad.1467606, 1635151, 17085481.
27. ter Steege JC, van de Ven WC, Forget P, Buurman WA. Regulation of lipopolysaccharide-induced NO synthase expression in the major organs in a mouse model. The roles of endogenous interferon-γ, tumor necrosis factor-α and interleukin-10. Eur Cytokine Netw 2000, 11:39-46.
28. Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N. Interleukin-10 is a central regulator of the response to LPS in murine models models of endotoxic shock and the Schwartzman reaction but not endotoxin tolerance. J Clin Invest 1995, 96:2339-2347. 10.1172/JCI118290, 185885, 7593621.
29. Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gérard C, Delvaux A. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994, 24:1167-1171. 10.1002/eji.1830240524, 8181527.
30. Márquez-Velasco R, Martínez-Velázquez AX, Amezcua-Guerra LM, Flores-Guzmán F, Díaz-Quiñonez A, Massó F. Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγF(ab')2 antibody fragments. Inflamm Res 2011, 60:947-953. 10.1007/s00011-011-0355-0, 21725677.
31. Cesaris P, Starace D, Riccioli A, Padula F, Filipinu A, Ziparo E. Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J Biol Chem 1998, 273:7566-7571. 10.1074/jbc.273.13.7566, 9516459.
32. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000, 161:1781-1785. 10.1164/ajrccm.161.6.9812004, 10852744.
33. Bekker L, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-α controls intracellular Mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001, 166:6728-6734.
34. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV. Protective effects of IL-6 blockade in sepsis are liked to reduced C5a receptor expression. J Immunol 2003, 170:503-507.
35. Liang B, Gardner D, Griswold D, Song X. Protection against lipopolysaccharide-induced death by an anti-IL-6 monoclonal antibody. Am J Immunol 2007, 3:4-9.
36. Morikawa A, Kato Y, Sugiyama T, Koide N, Chakravortty D, Yoshida T, Yokochi T. Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosamine-sensitized mice as an experimental endotoxic shock model. Infect Immun 1999, 67:1018-1024. 96424, 10024538.
37. Tsao CM, Huang HC, Chen ZF, Liaw WJ, Lue WM, Chen A, Chen SJ WUCC. Beneficial effects of hyperoncotic albumin on liver injury and survival in peritonitis-induced sepsis rats. Shock 2011, 35:210-216. 10.1097/SHK.0b013e3181f229f8, 20661179.
38. Nandi J, Saud B, Zinkievich JM, Yang ZJ, Levine RA. TNF-alpha modulate iNOS expression in an experimental rat model of indomethacin-induced jejunoileitis. Mol Cell Biochem 2010, 336:17-24. 10.1007/s11010-009-0259-2, 19802525.
39. Minsky A, Summers RG, Knowles JR. Secretion of beta lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci USA 1986, 83:4180-4184. 10.1073/pnas.83.12.4180, 323695, 3520569.
40. Barbas CF, Burton DR, Scott JK. Phage Display: A Laboratory Manual 2001, New York: Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
41. Hilgers J, van Nie R, Ivanyi D, Hilkens J, Michalides R, de Moes J, Poort-Keesom R, Kroezen V, von Deimling O, Kominami R, Holmes R. Genetic differences in BALB/c sublines. Curr Top Microbiol Immunol 1985, 122:19-30. 10.1007/978-3-642-70740-7_3, 2994956.